{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:43:50Z","timestamp":1790685830998,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.annder.2015.07.012","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T12:26:04Z","timestamp":1442060764000},"page":"729-735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["\u00c9valuation clinique de la s\u00e9v\u00e9rit\u00e9 de l\u2019hidrad\u00e9nite suppur\u00e9e \u2013\u00a0maladie de Verneuil"],"prefix":"10.1016","volume":"142","author":[{"given":"J.","family":"Revuz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2015.07.012_bib0005","series-title":"Dermatologic Surg","first-page":"729","article-title":"Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach","author":"Hurley","year":"1989"},{"key":"10.1016\/j.annder.2015.07.012_bib0010","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1\u00a0guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2015.07.012_bib0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2133.2003.05390.x","article-title":"Suggestions of uniform outcome variables when reporting treatment effects in hidradenitis suppurativa","volume":"149","author":"Sartorius","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2015.07.012_bib0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0151-9638(07)91613-0","article-title":"Modifications et mode d\u2019emploi du score de Sartorius pour \u00e9valuer la gravit\u00e9 de l\u2019hidrad\u00e9nite suppur\u00e9e","volume":"134","author":"Revuz","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2015.07.012_bib0025","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1365-2133.2010.09715.x","article-title":"Interobserver variability of clinical scores in hidradenitis suppurativa is low","volume":"162","author":"Sartorius","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2015.07.012_bib0030","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2015.07.012_bib0035","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annder.2015.07.012_bib0040","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2015.07.012_bib0045","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/bjd.13396","article-title":"Hidradenitis suppurativa outcome measures and treatment goals","volume":"171","author":"Ingram","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2015.07.012_bib0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2015.07.012_bib0055","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2015.07.012_bib0060","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaad.2006.08.061","article-title":"Quality of life impairment in hidradenitis suppurativa: a studyof 61\u00a0cases","volume":"56","author":"Wolkenstein","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2015.07.012_bib0065","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1468-3083.2012.04468.x","article-title":"Depression in patients with hidradenitis suppurativa","volume":"27","author":"Onderdijk","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2015.07.012_bib0070","first-page":"997","article-title":"The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results","volume":"159","author":"Basra","year":"2008","journal-title":"Br J Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963815004986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963815004986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:03:05Z","timestamp":1758970985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963815004986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0151963815004986"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2015.07.012","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9valuation clinique de la s\u00e9v\u00e9rit\u00e9 de l\u2019hidrad\u00e9nite suppur\u00e9e \u2013\u00a0maladie de Verneuil","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2015.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}